Coumarin derivative

a technology of coumarin and derivatives, applied in the field of medicaments, can solve the problems of significant deterioration of the qol (quality of life) of cancer patients, increase of doses, undesirable life-prolongation rate, etc., and achieve the effect of enhancing the effect of cancer therapy, reducing side effects, and reducing side effects

Inactive Publication Date: 2005-03-10
INST OF MEDICINAL MOLECULAR DESIGN
View PDF0 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention relates to a medicine that uses certain chemicals called guanidine to enhance the effectiveness of chemotherapy treatments against cancer cells caused by DNA damage. It also includes other substances like salicylic acid, chloroquinoxane, and others to reduce side-effects associated with these treatments.

Problems solved by technology

The technical problem addressed in this patent text relates to improving the effectiveness of chemotherapeutics in targeting tumors while reducing side effects associated with current treatment methods like radiation therapy and chemotherapy. Specifically, developing novel drugs or therapies that can specifically target specific types of cancer cells without causing harmful side effects, including those affecting healthy tissues, would benefit both patient groups and society.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Coumarin derivative
  • Coumarin derivative
  • Coumarin derivative

Examples

Experimental program
Comparison scheme
Effect test

example 1

Preparation of 2-chloro-N-(7-hydroxy-2-oxo-2H-1-benzopyran-3-yl)benzamide (Compound 2)

(1) Preparation of 3-amino-7-hydroxy-2H-1-benzopyran-2-one.

A mixture of N-(7-hydroxy-2-oxo-2H-1-benzopyran-3-yl)benzamide (230 mg, 0.82 mmol), 1-propanol (6 ml) and concentrated hydrochloric acid (2 ml) was refluxed for 3 hours. Then, hydrochloric acid (2 ml) was added and the mixture was refluxed for further 7 hours. After cooling, the reaction mixture was poured into saturated aqueous sodium hydrogen carbonate and extracted with ethyl acetate. The ethyl acetate layer was washed successively with water and saturated brine, and after the layer was dried over anhydrous sodium sulfate, the residue obtained by evaporation of the solvent under reduced pressure was purified by column chromatography on silica gel (eluent: dichloromethane / ethyl acetate=2 / 1) to give the title compound as a yellow solid (127 mg, 87.7%).

1H-NMR(DMSO-d6, δ): 5.23(2H, s), 6.65-6.70(3H, m), 7.23(1H, d, J=8.4 Hz), 9.81(1H,

example 2

Preparation of 3-chloro-N-(7-hydroxy-2-oxo-2H-1-benzopyran-3-yl)benzamide (Compound 3)

Yield: 38.8%

1H-NMR(CDCl3+DMSO-d6, δ): [2.58(a signal of DMSO)], 6.78(1H, d, J=2.4 Hz), 6.84(1H, dd, J=8.7, 2.4 Hz), 7.41(1H, d, J=8.4 Hz), 7.50(1H, t, J=7.5 Hz), 7.57(1H, ddd, J=7.8, 1.8, 1.5 Hz), [7.85(a signal of CHCl3)], 7.86(1H, dt, J=7.5, 1.5 Hz), 7.95-7.96(1H, m), 8.61(1H, s), 9.23(1H, s), 10.12(1H, s).

example 3

Preparation of 3-bromo-N-(7-hydroxy-2-oxo-2H-1-benzopyran-3-yl)benzamide (Compound 4)

Yield: 67.9%

1H-NMR(CDCl3+DMSO-d6, δ): [2.59(a signal of DMSO)], 6.86-6.89(2H, m), [7.37(a signal of CHCl3)], 7.39(1H, d, J=6.0 Hz), 7.42(1H, d, J=8.1 Hz), 7.71(1H, ddd, J=7.8, 1.8, 1.2 Hz), 7.83(1H, ddd, J=7.8, 1.8, 1.2 Hz), 8.06(1H, t, J=1.8 Hz), 8.73(1H, s), 8.76(1H, s), 9.79(1H, s).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A medicament for enhancing an effect of a cancer therapy based on a mode of action of DNA injury, which comprises as an active ingredient a compound represented by the following general formula (I):
wherein X represents a single bond or a C1 to C6 alkylene group which may be substituted; A represents a C1 to C6 alkyl group which may be substituted, a C6 to C10 aryl group which may be substituted, or a 4 to 10-membered monocyclic or bicyclic and unsaturated, partly saturated, or completely saturated heterocyclic group which may be substituted, wherein said heterocyclic group comprises as ring-constituting atoms 1 to 4 hetero atoms selected from the group consisting of nitrogen atom, oxygen atom, and sulfur atom.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Owner INST OF MEDICINAL MOLECULAR DESIGN
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products